These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2094334)

  • 1. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.
    Bartlett AN; Hoffbrand AV; Kontoghiorghes GJ
    Br J Haematol; 1990 Oct; 76(2):301-4. PubMed ID: 2094334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
    Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV; Goddard JG; Sheppard L; Barr J; Nortey P
    Br J Haematol; 1990 Oct; 76(2):295-300. PubMed ID: 2094333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
    al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
    Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
    Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R
    Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
    Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
    Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
    Agarwal MB; Gupte SS; Viswanathan C; Vasandani D; Ramanathan J; Desai N; Puniyani RR; Chhablani AT
    Br J Haematol; 1992 Oct; 82(2):460-6. PubMed ID: 1419829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferiprone-associated myelotoxicity.
    al-Refaie FN; Wonke B; Hoffbrand AV
    Eur J Haematol; 1994 Nov; 53(5):298-301. PubMed ID: 7813710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
    Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
    J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
    al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
    J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
    Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
    Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
    Olivieri NF; Templeton DM; Koren G; Chung D; Hermann C; Freedman MH; McClelland RA
    Ann N Y Acad Sci; 1990; 612():369-77. PubMed ID: 2291564
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
    Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
    Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term treatment of patients with transfusion hemosiderosis using oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1)].
    Goudsmit R
    Ned Tijdschr Geneeskd; 1991 Nov; 135(45):2133-6. PubMed ID: 1944690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
    Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
    J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
    Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
    Kontoghiorghes GJ
    Indian J Pediatr; 1993; 60(4):485-507. PubMed ID: 8262586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
    Cermak J; Jonasova A; Vondrakova J; Walterova L; Hochova I; Siskova M; Neuwirtova R
    Hemoglobin; 2011; 35(3):217-27. PubMed ID: 21599434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.